Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 30

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Non-small cell lung cancer+1

Recruiting

Study of LN-145 (Tumor Infiltrating Lymphocytes) in patients with metastatic non-small-cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Respiratory failure

Recruiting

Study on the Effects of Iloprost Trometamol in Patients with Infectious Lung Disease on Mechanical Ventilation

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Iloprost Trometamol
  • Sponsor:Region Hovedstaden

Eosinophilic granulomatosis with polyangiitis

Recruiting

Study on the Effectiveness and Safety of NS-229 for Patients with Eosinophilic Granulomatosis with Polyangiitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methyl-(1-{[6-{[(1S)-1-Cyclopropylethyl]Amino}-2-(Pyrazolo[5,1-B][1,3]Thiazol-7-Yl)-Pyrimidin-4-Yl]Carbonyl}Piperidin-4-Yl)Carbamate-Mono(4-Methylbenzenesulfonate) Monohydrate
  • Sponsor:Ns Pharma Inc.

Alpha-1 antitrypsin deficiency

Recruiting

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Colorectal cancer+3

Recruiting

Study on Tislelizumab for Cancer Patients with Molecular Residual Disease After Standard Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Institut Gustave Roussy

Pulmonary embolism+7

Recruiting

Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rosuvastatin Calcium
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Non-small cell lung cancer

Recruiting

Study of EXL-01 and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Exl01
  • Sponsor:Centre Hospitalier Universitaire De Lille

Neoplasm+5

Recruiting

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Wheezing+1

Recruiting

Study on Oral Prednisolone and Sucrose for Treating Wheezing Caused by Rhinovirus in Children Under 2 Years Old

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Sucrose
  • Sponsor:University Of Oulu

Non-small cell lung cancer

Recruiting

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer

Recruiting

Study of NVL-520 for Patients with Advanced ROS1-Positive Lung Cancer and Other Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Zidesamtinib
  • Sponsor:Nuvalent Inc.

Endometrial cancer+4

Recruiting

Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pc14586
  • Sponsor:Pmv Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.